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This report is based on the transcript of a roundtable debate
held at the 23rd International Symposium on Intensive Care
and Emergency Medicine (ISICEM), Brussels, Belgium,
18–21 March 2003. The participants of the debate were
Jean-François Dhainaut (Paris, France), Stephan Harbarth
(Geneva, Switzerland), Konrad Reinhart (Jena, Germany),
John C Marshall (Toronto, Canada) and Mitchell Levy
(Providence, USA).
[Herwig Gerlach] We will now continue with the ‘R’. The R is
for response. We had the definition from SIRS [systemic
inflammatory response syndrome], which has been
discussed, and SIRS was a stratification. Now we’re
discussing R as a new possibility to quantify the response,
and this would be my first, maybe a little bit provocative,
question.
We’ve heard that the grade of response is not always
predictive of outcome; for instance, you might remember the
cartoon in the New England Journal of Medicine by
Hotchkiss, where he said that patients who are not
responding are obviously clinically more at risk than those
with a very visible response. So my question is, is it
necessary to quantify response or do we need to find a new
way of stratification, of qualifying response, or not?
[Mitchell Levy] That’s very interesting – I think it has to be
both. The whole purpose of PIRO is to stratify rather than
quantify, and I think that as a hypothesis-generating model
the idea is, can we figure out how to stage sepsis more
accurately and precisely so that we might be able to time our
interventions better. Right now, for instance, the agents that
we use that have been shown to improve survival are for
severe sepsis. Well, severe sepsis is such a crude definition
because you have to wait until there’s frank organ
dysfunction. So if we could get a better stratification model
that allowed us, based on biomarkers, for instance the ‘R’, to
identify what patients are at risk for developing organ
dysfunction, and then test that hypothesis to see if
interventions reduce the degree to which organ dysfunction
develops, then that is an important stratification. The actual
quantification is necessary in order to create the model; how
much IL-6, how much TNF [tumour necrosis factor], etc., is
important, but more important is the stratification of profiles
for biomarkers.
[HG] But this would consider that we have the conclusion
that the higher the response the higher the risk. But is this
really the case?
[John C Marshall] I agree, the intent here is to stratify rather
than quantify the severity. But the other concept behind
PIRO that I think is important is an attempt to deconstruct
sepsis, because we’ve kind of regressed to a mindset where
we’re talking about a single large definable, homogeneous
population of patients. So is it important to measure the
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response? That depends on the circumstances, and I think
we need to define it by what we’re going to do. If our
intervention is continuous veno-venous haemodialysis, then it
doesn’t matter what the temperature is, it doesn’t matter
what the IL-6 is – we’re treating renal failure as a component
of the syndrome of sepsis. If our intervention is an antibiotic
then it’s probably going to work better in patients who don’t
have a really dramatic response, because those will tend to
be patients in whom the disease is driven by the effects of
the organism. On the other hand, if our intervention is an
anticoagulant then clearly the response we want to look at is
whether there is evidence of a coagulopathy that might
stratify that patient into a more homogeneous population with
response to therapy we’re going to give.
Taking the notion, which I think is reasonable, that there are
some patients who are sick because they are
hyperresponsive and some patients who are sick because
they are hyporesponsive, clearly if we lump those together
we’re never going to see a benefit for any therapy because
it’s going to help half the patients, harm half the patients, and
the net effect will be zero. But if our intervention is something
that is going to boost the immune response then it’s critical
that we define the response and we explicitly define it as
hyporesponsiveness, just as Annane et al. showed that
patients who are relatively steroid adrenal insufficient are
those that respond to corticosteroids.
[Konrad Reinhart] I think this comes to the point of biological
plausibility of the markers that we are measuring. As you said,
if you want to treat with an anticytokine it might be wise to
look for cytokines, and there IL-6 would be appropriate as a
surrogate marker. And in fact this is the only marker so far that
has identified a higher risk of dying because, in these two
large studies, patients who had higher IL-6 levels had a clearly
higher mortality, and the question is, why are we measuring
response? Is it to titrate a specific therapy, or to have
prognostic information? That’s why we should not only talk
about appropriate markers for the response but also discuss
the cause of the response. What we all know from studies is
that a person with a persistently high procalcitonin (PCT) is
very unlikely to survive. We can discuss new markers like
pro-ANP [pro-atrial natriuretic peptide] that has a high
likelihood for predicting outcome very early and maybe also
BNP [brain natriuretic peptide], so this response issue has to
be looked at for the reasons that are relevant to our therapy.
There may be markers that have a high potential for prognosis
and maybe other markers to tell us how successful we are
with therapy, or specifically predict how the patient might
respond. Also, we must use not just immunosuppressive
therapies but also immunoaugmentive therapies, where we
should look at IL-10 or other anti-inflammatory mediators. We
have some data but we should do further work.
[HG] So may I conclude that there is a necessity for
quantifying? So let’s look at how we can do this – starting
with clinical features. Do you think that it’s necessary or good
and useful to measure fever and white blood count – the
traditional markers used in the SIRS criteria?
[Jean-François Dhainaut] I think first it’s very important to
understand that the response depends not only on the
infectious process, for instance the white blood cells for
haematologic patients, heart rate in patients with cardiac
disease or patients taking drugs that interfere with this
cardiac response. Responses can also be very different in
the elderly; often their responses are a bit lower, and
sometimes you have no fever, white blood cells are not so
high, and also regarding the markers. As an example, in the
PROWESS trial elderly patients usually had relatively
inflammatory symptoms, taking into account the coagulation
and inflammatory biomarkers. Likewise, patients with some
underlying disease may have lower inflammatory and
coagulation responses.
So the question is, how important is it to quantify the
response regarding the clinical side or the biological side? I
think a single measurement may not be so important but its
time course is more interesting because we can modify it
with treatment.
[A participant] I would take an extreme stance. First of all, I
think that the R is the most important part of PIRO, and I
think that the clinical signs and symptoms will fall by the
same way as SIRS criteria fell, because I think that most of
us assume that clinical signs and symptoms of infection are
surrogates for biomarkers. We certainly know that about
fever and IL-1, and I think that over the next 5–10 years – and
it’s already happening – clinical trials are adding proteonomic
arms and collecting large volumes of biomarker data,
sequentially, over time. I predict, or hope, that once we have
the ability to get profiles of those biomarkers for identification
of patients in the early phases, for identification of patients
who are progressing, and then respond to therapy, we won’t
be looking at clinical signs and symptoms any more.
[Stephan Harbarth] I wouldn’t completely throw away SIRS
since it has a high sensitivity to detect septic patients. If there
is something particular useful in SIRS it has probably to do
with the white blood count (WBC) and left shift. We saw in a
couple of studies that if you take into account leukocytosis
plus the left shift and you add, perhaps, procalcitonin or
lactate – something that is easily available at the bedside – I
think for the next couple of years this may remain a pretty
good marker for response. After all, we have been talking
about all these cytokine cocktails for 10 years and look
what’s really used at the moment. I remind you that in the
USA, they’ve just introduced CRP [C-reactive protein];
something that most European critical care physicians don’t
understand is that for 10 years CRP was not available in
most U.S. hospitals. So let's get practical, and let’s speak
about what’s really going to be important in the next258
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2–3 years. I think we should consider blood gases, pH,
lactate, differential WBC and procalcitonin as markers for
systemic response
[JCM] I just wanted to make a big-picture comment, and that
is how to approach this whole notion of thinking about a
stratification system for sepsis. We can all talk about what
are our favourite markers for sepsis, or how we see a
complex disease process, but I would hope that what we can
generate here is a whole series of good questions to ask and
evaluate in clinical trials. Something as simple as what you’re
asking, Herwig, is: is fever important? The way you’d transfer
this into a research question is, does the patient’s
temperature at onset of therapy alter response to therapy?
Another question is, is the response to therapy reflected in an
alteration in temperature? The important one for the PIRO
model is, is temperature a stratification variable that will
define, for example, relative increased success of therapy
with a broad-spectrum carbapenem in a patient with
ventilator-related pneumonia? So it’s thinking of a whole
series of contingent questions that can be answered. It’s
fairly simple database-driven observational studies that we
should be working on, rather than trying to a priori impose
our particular view of the world on a process that we clearly
don’t understand very well right now.
[HG] One problem was that SIRS was a black and white
stratification – it was never evaluated over time. So this leads
of course to parameters or any variables that are feasible to
monitor the state of the patient, and why do you think there
are so many differences between the US and Europe, for
example, in PCT, CRP [C-reactive protein]? Do you have any
idea why this is the case?
[JCM] As a Canadian – someone who is neutral in this issue
– I think it actually gets back to the ‘P’ of the PIRO model.
There are some very important cultural differences that define
the way we institute therapy, and it’s clear to me that North
Americans don’t believe in CRP and PCT in part because
they originated in Europe, and I suspect there are probably
similar views among Europeans about things that originated
in North America. And more power to you!
[SH] There are some North Americans who have some
consideration for PCT or who are pretty curious about PCT,
and I think that, just coming back to what’s practical
nowadays, some studies have shown that PCT may be a
good surrogate marker for the other cytokine cocktails going
on. High PCT levels are well correlated with TNF levels and
other marker levels. So my suggestion for future clinical trials
is to add PCT and test the hypothesis that by stratifying
according to PCT one may predict outcomes.
[KR] I think this is another good point – feasibility. I think for
PCT the technical requirements have been improved
rapidly. We have to learn to which of our various treatments
that we apply in sepsis our biomarkers respond best. We
often don’t know whether it’s due to the antibiotic that our
patient gets better or if it’s because we took out his
catheter, which was contaminated, or even if it is because
we have improved our oxygen delivery; data were recently
presented that the serum of patients with a central venous
O2 pressure below 50% had a strong inflammatory
response. If we learn which of these new biomarkers best
reflect our various treatment strategies, then we can use
this also for the response to therapy. But primarily it’s a
response to the insult.
[JCM] I agree. First, it’s important to say that PIRO is really
meant as a hypothesis-generating model. None of us are
introducing it with the idea that tomorrow we’ll go look at a
patient and work out their PIRO score. Really it’s a way of
introducing the field to a new way of stratifying response to
infection. So from that point of view, the R is clearly the
response to infection, but as you intervene the R changes.
So you could go from an R2 to an R3, based on how you
define response; well, that’s the response to therapy – but
it’s still R as the response to infection, but within that there’s
a response to therapy.
[Audience member] I agree with those comments, and the
other thing to keep in mind is that this is a template that
could be applied to virtually every disease in medicine. The
reason we’re doing it in the context of sepsis is that the
questions we have to answer to study this entity are probably
more complex than any other area of medicine. In cardiology,
for example, the R could be a rapid heart rate in a patient
with a supraventricular tachycardia, that’s the patient you
would treat with an antiarrhythmic, but you would anticipate
that the R would also be the response – i.e. that the rate
would come down.
A corollary of that is a huge mistake we’ve made in sepsis
trials, which is thinking that we can enroll patients based on a
certain group of entry criteria but that we wouldn’t anticipate
that these would get better. If they’re important stratification
variables to select patients for a trial then they should be
altered by therapy, and if they’re not then they’re not useful
for stratification.
Sepsis typically arises as a complication of other disease
processes; one could even argue that it’s a complication of a
pneumococcal pneumonia rather than a pneumococcal
pneumonia per se. So clearly that lead-time bias is
intrinsically the entity of the disease, and part of the reason
why we have to think about – Where did we start? What was
the stimulus? What was the response? What has happened
so far? – is that if the damage has already been done then
trying to modify the initiating stimulus is unlikely to affect the
outcome. We’re going to have to focus on therapies that are
going to modulate the subsequent response to that injury, to
the damage that has been done, to the organ dysfunction.259
[J-FD] Another point is the difficulty to separate the pro- and
the anti-inflammatory process, and to assess the balance
between the two. For example, IL-6 is a pro- and anti-
inflammatory cytokine. When you correlate prognosis with a
cytokine, it appears that IL-10 is better than TNF, or rather
the balance between TNF and IL-10. There was a paper in
The Lancet showing that patients who have an imbalance
between TNF and IL-10 have a poor prognosis. It’s the same
for the coagulation process, where coagulation is activated
and anticoagulant factors consumed. It is very difficult to
influence the coagulation system because the two
possibilities are rapidly inhibited, fibrinolysis and
anticoagulation.
[ML] I think that’s exactly why SIRS is inadequate because
when we look at one clinical sign and symptom, or two out of
four, it’s the same thing as if you looked at just one cytokine.
So as our understanding of the pathophysiology of the
inflammatory response to infection deepens, we begin to
realize you can’t just look at IL-6, you can’t just look at a
proinflammatory or even just an anti-inflammatory marker. We
need the constellation of response in terms of markers. So I
think that’s exactly why stratification is important.
[KR] It might well be that GSF [growth-stimulating factor]
administration, which turned out to be negative, might have
worked had we looked at it only in patients with leukopenia or
who would have been immunosuppressed by other markers,
and interferon-γ. One reason why I like PCT is that it helps
me differentiate, for example, between patients with infection-
related organ dysfunction and non-infection-related organ
dysfunction. A fundamental question to me is whether I have
the right antibiotic or not. So they are separate questions.
[Audience member] One of the things that I’m having a hard
time with is, does it make any difference whether it leads to
organ dysfunction, and especially in those who have the
genetic factors responsible for greater release of IL-8 etc.
What I’m hearing you say is that you need to specify a marker
for the specific intervention that you’re trying to study – that
there needs to be some surrogate in there somewhere. From
a practical standpoint, there are many markers with unclear
relationships to specific disease.
[JCM] Let me give you an example of that. We did an analysis
of patients in the MONARCH anti-TNF study, who’d had
some sort of source control done. We did a blinded analysis
of the adequacy of source control. Now, in that study
patients were stratified on the basis of their IL-6 level, and
what we found was that if you looked at the impact of
adequate source control, there was a 16% survival
improvement for patients who had adequate source control,
even in the group with low IL-6 levels. But the benefits of
adequate source control were less clear. There was no
evidence that the adequacy of source control impacted on
outcome in the patients with high IL-6 levels; it was an
insignificant effect. What that means is that if the intervention
we’re looking at is, for example, a source control with surgical
therapy and antibiotics, then we’re probably going to see a
maximum signal where we’re going to want to exclude
patients who have an activated response, or the disease
process is now being driven by the response rather than by
the original stimulus.
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